Neuroendocrine Tumors Treatment Market - Size, Share and Forecast (2019-2026)

SKU: DHC81 | Last Updated On: 2019-05-17 | No. of Pages: 220 | Available Formats

( 36 Samples have been requested. )
In October 2018, Lutathera by Novartis AG received FDA approval for the first-ever radionucleotide therapy.

Neuroendocrine Tumors Treatment Market

Global Neuroendocrine Tumors Treatment Market

The global neuroendocrine tumors treatment market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.

Neuroendocrine tumors (NETs) are caused by abnormal growth of neoplasms that originate from hormone-producing cells of endocrine glands and nervous systems. NETs may develop anywhere in the body, such as intestines, stomach, pancreas, and lungs, that makes diagnosis difficult at early stages. NETS are a rare malignant disorder that accounts for only around 1% of all malignant disorders. NETs can be either symptomatic or asymptomatic. They generally affect intestine and pancreas. Some common symptoms of NETs include hyperglycemia, hypoglycemia, weight loss, loss of appetite, headache, anxiety, gastric ulcer, unusual bleeding, jaundice, diarrhea, fever, and persistent in a specific area.

The treatment adopted for NETs focuses on controlling underlying symptoms and complications related to the progression of the disease. Treatment options include surgery, radiation therapy, and chemotherapy. Surgery is considered as the first option for the treatment of NETs, but as the disease is majorly asymptomatic it is diagnosed when the disease has reached metastatic stage and surgery is no longer a viable treatment option. Targeted therapy and somatostatin analogs have gained immense popularity over the last decade for the treatment of NETs as they control the symptoms, target biomarkers, and control the growth of cancer. Molecular targeted therapy comprising of drugs such as Everolimus and Sunitinib is adopted as a first-line treatment due to fewer side effects associated with the targeted therapy. Somatostatin analogues are preferred by surgeons for those patients who are resistant to surgery and radiation therapy.

According to Novartis, each year, 5.25 out of every 100,000 people in the US are diagnosed with NETs.

Global Neuroendocrine Tumors Treatment Market Drivers

The market is driven by increased cases of NETs, heavy investment by various pharmaceutical companies for clinical trials of novel products, technological advancements in therapies, robust pipeline and increased funding by many government and non-government organizations.

One of the key factor driving the growth of the global neuroendocrine tumors treatment market is increasing research grants and funding by many government and non-government organizations like the American Cancer Society and the World Health Organization (WHO). Many major companies in the market are trying to create awareness about NETs. Organizations are giving clinical assistance for the treatment of NETs. These grants are aimed to study NETs, which are commonly misdiagnosed. In February 2019, the Neuroendocrine Tumor Research Foundation (NETRF) received eight new grants totaling $2.5 million for research on neuroendocrine cancer. With this newest round of funding, NETRF is going to expand its portfolio to include research into lung neuroendocrine tumors. Similarly, the Neuroendocrine Tumour Research Foundation (NETRF), invested around $1.5 million for the development of advanced radiation therapy – Peptide Receptor Radionuclide Therapy (PRRT).

Several organizations globally are conducting national and international programs to increase awareness about NETs for early diagnosis and treatment. For instance, the International Neuroendocrine Cancer Alliance (INCA) observes the neuroendocrine day on November 10, every year. The increase in awareness programs is going to play a huge role in the growth of the market.

Global Neuroendocrine Tumors Treatment Market Restraints

Lack of skilled healthcare professionals and lower adoption of advanced treatment technologies

are going to restrain the market in the forecast period.

Pipeline Analysis

Various ongoing researches on NET are related to immunotherapy. Researchers are testing novel cancer vaccines on NETs and drugs that block Programmed cell death protein 1 (PD-1).

In May 2016, the FDA approved a PD-L1 inhibitor, atezolizumab (Tecentriq) by Roche, in combination with carboplatin and etoposide chemotherapy. Chimeric antigen receptor therapy (CAR T-cell therapy) combined with antibody-drug conjugates is also being explored as target therapy. Some other ongoing clinical trials include RAD 001 by Novartis to treat advanced midgut NETs, Lanreotide Autogel manufactured by Ispen for non-functional tumors, and NET-01 chemotherapy for pancreatic tumors.

Global Neuroendocrine Tumors Treatment Market Segmentation

The global neuroendocrine tumors treatment market can be segmented by treatment type as Surgery, drug therapy, Interventional Radiology and Nuclear Medicines. Drug therapies are further segmented as Somatostatin Analogs, Targeted Therapy and Immunotherapy, Chemotherapy and Nuclear Medicine, Interventional Radiology is further segmented as Hepatic Embolization and Radiofrequency Ablation. By treatment site market can be segmented into Gastrointestinal, Pancreas, Lung, and Others.

The Somatostatin Analogs and Targeted Therapy are widely used for the treatment of NETs as they control cancer growth, symptoms, and target biomarkers. Many Somatostatin Analogs are currently under clinical trial phase and waiting for approval. For instance, PEN-221 by Tarveda Therapeutics and DP1038 by Dauntless Pharmaceuticals. Targeted therapy consists of drugs, such as Sunitinib and Everolimus. Targeted therapy has relatively lesser side effects than other treatment options.

The gastrointestinal segment is expected to account for the largest market over the period of the forecast as the gastrointestinal tract is more prone to NETs. According to the statistics published by Novartis in 2015, around 61% of the total NETs are in the gastrointestinal tract. Moreover, according to the American Society of Clinical Oncology (ASCO), in 2018, around 10,000 adults in the U.S. were diagnosed with gastrointestinal NETs.

Global Neuroendocrine Tumors Treatment Market Geographical Analysis

Geographically, the global neuroendocrine tumors treatment market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.

Technological advancement in targeted therapy and enhanced funding in the research and development sector is helping boost the North America neuroendocrine tumors treatment market. As per Cancer.Net, it is estimated that more than 12,000 people in the US are diagnosed with a NET each year, and approximately 170,000 people are living with one. The number of people diagnosed with this type of tumor is increasing by more than 5% each year. Patients undergoing NETs treatment in the US are supported by insurance policies such as Medicaid, Tricare, and Medicare. Many of the major companies in this segment have headquarters in the US and thus consider North America as their primary market for product launch and investment.

Global Neuroendocrine Tumors Treatment Market Competitive Analysis

Some of the major key players in the market are Pfizer, Inc., Novartis AG, Ipsen Pharma, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics and Boehringer Ingelheim International GmbH. Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma.

In October 2018, Novartis announced a new analysis of Lutathera® at the 2018 European Society for Medical Oncology (ESMO) Congress examining the impact of Lutathera treatment on patients with low, medium, or high liver tumor burden. The data show that Lutathera treatment results in significant improvement in progression-free survival.

In October 2018, Novartis entered into a merger with Endocyte, a US-based biopharmaceutical company. Novartis acquired all outstanding shares of Endocyte common stock.

In June 2018, Boehringer Ingelheim laid the foundation stone for Boehringer Ingelheim Biologicals Development Centre in Biberach, Germany. The company is making an estimated investment of $266.4 million. The center will specialize in immune-oncology and immunology.

In January 2018, Novartis AG announced to purchase all the ordinary shares from its subsidiary group Novartis Groupe France S.A., which includes Advanced Accelerator Applications S.A.

Why purchase the report?

·        Visualize the composition of the neuroendocrine tumors treatment market across each indication, in terms of type and by type highlighting the key commercial assets and players.

·        Identify commercial opportunities in neuroendocrine tumors treatment by analyzing trends and co-development deals.

·        Excel data sheets with thousands of data points of neuroendocrine tumors treatment market- level 4/5 segmentation.

·        PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

·        Product mapping in excel for the key products of all major market players.

Target Audience:

  • Medical device companies
  • Hospitals and clinics
  • Research and consulting firms
  • Healthcare associations/institutes
  • Venture capitalists
  • Government agencies

1. Global Neuroendocrine Tumors Treatment Market Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2.  Global Neuroendocrine Tumors Treatment Market – Market Definition and Overview

3.Global Neuroendocrine Tumors Treatment Market – Executive Summary

3.1. Market Snippet by Treatment Type

3.2.Market Snippet by Treatment Site

3.3. Market Snippet by Region

3.4.DataM CLO Scenario

4.Global Neuroendocrine Tumors Treatment Market – Market Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1.Increased cases of NETs

4.1.1.2.Heavy investment by various pharmaceutical companies

4.1.1.3.Technological advancements in therapies

4.1.1.4.Increased funding by many government and non-government organizations

4.1.2. Restraints

4.1.2.1.Lack of skilled healthcare professionals

4.1.2.2.Lower adoption of advanced treatment technologies

4.1.3. Opportunity

4.1.4. Impact Analysis

5.Global Neuroendocrine Tumors Treatment Market – Industry Analysis

5.1. Porter's Five Forces Analysis

5.2. Regulatory Analysis

5.3. Epidemiology

5.4. Treatment Algorithm

5.5.  Technology Advances

5.6.Patent Analysis

6.Global Neuroendocrine Tumors Treatment Market – Pipeline Analysis

6.1. Pipeline Overview

6.2.Key Pipeline Drug Profiles

7.Global Neuroendocrine Tumors Treatment Market – By Treatment Type

7.1. Introduction

7.2.Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

7.3.Market Attractiveness Index, By Treatment Type

7.4.Surgery

7.4.1. Introduction

7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

7.5. Drug Therapies

7.5.1.  Somatostatin Analogs

7.5.2. Immunotherapy and Targeted Therapies

7.5.3. Chemotherapy

7.5.4. Nuclear Medicines

7.6.Interventional Radiology

7.6.1. Hepatic Embolization

7.6.2. Radiofrequency Ablation

8.Global Neuroendocrine Tumors Treatment Market – By Treatment Site

8.1.Introduction

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

8.3. Market Attractiveness Index, By Treatment Site

8.4.Gastrointestinal

8.4.1. Introduction

8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

8.5.Pancreas

8.6.Lung

8.7.Others

9.Global Neuroendocrine Tumors Treatment Market – By Region

9.1. Introduction

9.2.Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

9.3.Market Attractiveness Index, By Region

9.4.North America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.4.5.1.U.S.

9.4.5.2.Canada

9.4.5.3.Mexico

9.5.Europe

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.5.5.1.Germany

9.5.5.2.U.K.

9.5.5.3.France

9.5.5.4.Italy

9.5.5.5 .Spain

9.5.5.6.Rest of Europe

9.6.South America

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.6.5.1.Brazil

9.6.5.2.Argentina

9.6.5.3.Rest of South America

9.7.Asia-Pacific

9.7.1. Introduction

9.7.2. Key Region-Specific Dynamics

9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.7.5.1.China

9.7.5.2.India

9.7.5.3.Japan

9.7.5.4.Australia

9.7.5.5.Rest of Asia Pacific

9.8.Middle East and Africa

9.8.1. Introduction

9.8.2. Key Region-Specific Dynamics

9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Site

10. Global Market – Competitive Landscape

10.1.Competitive Scenario

10.2.Competitor Neuroendocrine Tumors Treatment Strategy Analysis

10.3.Comparative Product Portfolio Analysis

10.4.Market Positioning/Share Analysis

10.5.Mergers and Acquisitions Analysis

11. Company Profiles

11.1.Pfizer, Inc. *

11.1.1.Company Overview

11.1.2.Product Portfolio and Description

11.1.3.Key Highlights

11.1.4.Financial Overview

11.2.Novartis AG

11.3.Ipsen Pharma

11.4.Dauntless Pharmaceuticals, Inc.

11.5.Exelixis, Inc.

11.6.Hutchinson

11.7.Medipharma Limited

11.8.Progenics Pharmaceuticals, Inc.

11.9.Tarveda Therapeutics

11.10.Boehringer Ingelheim International GmbH

12. Global Neuroendocrine Tumors Treatment Market – Premium Insights

13. Global Neuroendocrine Tumors Treatment Market – DataM

13.1.Appendix

13.2.About Us and Services

13.3.Contact Us

List of Tables

Table 1 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 2 Global Neuroendocrine Tumors Treatment Market Value, By Therapies, 2018,2022 & 2026 ($ Million)

Table 3 Global Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2018,2022 & 2026 ($ Million)

Table 4 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2018,2022 & 2026 ($ Million)

Table 5 Global Neuroendocrine Tumors Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 6 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 7 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 8 Global Neuroendocrine Tumors Treatment Market Value, By Therapies, 2018,2022 & 2026 ($ Million)

Table 9 Global Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 10 Global Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2018,2022 & 2026 ($ Million)

Table 11 Global Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 12 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2018,2022 & 2026 ($ Million)

Table 13 Global Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 14 Global Neuroendocrine Tumors Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 15 Global Neuroendocrine Tumors Treatment Market Value, By Region, 2017-2026 ($ Million)

Table 16 North America Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 17 North America Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 18 North America Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 19 North America Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 20 North America Neuroendocrine Tumors Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 21 South America Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 22 South America Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 23 South America Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 24 South America Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 25 South America Neuroendocrine Tumors Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 26 Europe Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 27 Europe Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 28 Europe Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 29 Europe Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 30 Europe Neuroendocrine Tumors Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 31 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 32 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 33 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 34 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 35 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 36 Middle East & Africa Neuroendocrine Tumors Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 37 Middle East & Africa Neuroendocrine Tumors Treatment Market Value, By Therapies, 2017-2026 ($ Million)

Table 38 Middle East & Africa Neuroendocrine Tumors Treatment Market Value, By Interventional Radiology, 2017-2026 ($ Million)

Table 39 Middle East & Africa Neuroendocrine Tumors Treatment Market Value, By Treatment Site, 2017-2026 ($ Million)

Table 40 Pfizer Inc.: Overview

Table 41 Pfizer Inc.: Product Portfolio

Table 42 Pfizer Inc.: Key Developments

Table 43 Novartis AG: Overview

Table 44 Novartis AG: Product Portfolio

Table 45 Novartis AG: Key Developments

Table 46 Ipsen Pharma: Overview

Table 47 Ipsen Pharma: Product Portfolio

Table 48 Ipsen Pharma: Key Developments

Table 49 Dauntless Pharmaceuticals Inc.: Overview

Table 50 Dauntless Pharmaceuticals Inc.: Product Portfolio

Table 51 Dauntless Pharmaceuticals Inc.: Key Developments

Table 52 Exelixis Inc.: Overview

Table 53 Exelixis Inc.: Product Portfolio

Table 54 Exelixis Inc.: Key Developments

Table 55 Hutchinson: Overview

Table 56 Hutchinson: Product Portfolio

Table 57 Hutchinson: Key Developments

Table 58 Medipharma Limited: Overview

Table 59 Medipharma Limited: Product Portfolio

Table 60 Medipharma Limited: Key Developments

Table 61 Progenics Pharmaceuticals Inc.: Overview

Table 62 Progenics Pharmaceuticals Inc.: Product Portfolio

Table 63 Progenics Pharmaceuticals Inc.: Key Developments

Table 64 Tarveda Therapeutics: Overview

Table 65 Tarveda Therapeutics: Product Portfolio

Table 66 Tarveda Therapeutics: Key Developments

Table 67 Boehringer Ingelheim International GmbH: Overview

Table 68 Boehringer Ingelheim International GmbH: Product Portfolio

Table 69 Boehringer Ingelheim International GmbH: Key Developments


List of Figures

Figure 1 Global Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 2 Global Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 3 Global Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 4 Global Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 5 Global Neuroendocrine Tumors Treatment Market Share, By Region, 2018 & 2026 (%)

Figure 6 Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 7 Global Neuroendocrine Tumors Treatment Market Y-o-Y Growth, By Treatment Type, 2018-2026 (%)

Figure 8 Surgery: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 9 Therapies: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 10 Intraventional Radiology: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 11 Nuclear Medicines: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 12 Global Neuroendocrine Tumors Treatment Market Y-o-Y Growth, By Therapies, 2018-2026 (%)

Figure 13 Somatostatin Analogs: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 14 Targeted Therapy: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 15 Chemotherapy: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 16 Immunotherapy: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 17 Global Neuroendocrine Tumors Treatment Market Y-o-Y Growth, By Interventional Radiology, 2018-2026 (%)

Figure 18 Hepatic Embolization: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 19 Radiofrequency Ablation: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 20 Global Neuroendocrine Tumors Treatment Market Y-o-Y Growth, By Treatment Site, 2018-2026 (%)

Figure 21 Gastrointestianl: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 22 Pancreas: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 23 Lung: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 24 Others: Global Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 25 Global Neuroendocrine Tumors Treatment Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 26 North America Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 27 North America Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 28 North America Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 29 North America Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 30 North America Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 31 North America Neuroendocrine Tumors Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 32 South America Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 33 South America Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 34 South America Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 35 South America Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 36 South America Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 37 South America Neuroendocrine Tumors Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 38 Europe Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 39 Europe Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 40 Europe Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 41 Europe Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 42 Europe Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 43 Europe Neuroendocrine Tumors Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 44 Asia-Pacific Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 45 Asia-Pacific Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 46 Asia-Pacific Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 47 Asia-Pacific Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 48 Asia-Pacific Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 49 Asia-Pacific Neuroendocrine Tumors Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 50 Middle East & Africa Neuroendocrine Tumors Treatment Market Value, 2017-2026 ($ Million)

Figure 51 Middle East & Africa Neuroendocrine Tumors Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 52 Middle East & Africa Neuroendocrine Tumors Treatment Market Share, By Therapies, 2018 & 2026 (%)

Figure 53 Middle East & Africa Neuroendocrine Tumors Treatment Market Share, By Interventional Radiology, 2018 & 2026 (%)

Figure 54 Middle East & Africa Neuroendocrine Tumors Treatment Market Share, By Treatment Site, 2018 & 2026 (%)

Figure 55 Pfizer Inc.: Financials

Figure 56 Novartis AG: Financials

Figure 57 Ipsen Pharma: Financials

Figure 58 Dauntless Pharmaceuticals Inc.: Financials

Figure 59 Exelixis Inc.: Financials

Figure 60 Hutchinson: Financials

Figure 61 Medipharma Limited: Financials

Figure 62 Progenics Pharmaceuticals Inc.: Financials

Figure 63 Tarveda Therapeutics: Financials

Figure 64 Boehringer Ingelheim International GmbH: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report